Minimally invasive and non-invasive market seen reaching $216.48 billion by 2030

The Business Research Company says the global market for minimally invasive and non-invasive products and services will grow from $160.81 billion in 2026 to $216.48 billion by 2030, driven by chronic disease demand, robotic surgery and outpatient care. North America held the largest share in 2025, with advanced healthcare infrastructure helping sustain adoption.

Why it matters: - Minimally invasive and non-invasive procedures are gaining share because they can reduce risk, pain and recovery time versus traditional surgery. - The market’s projected expansion signals continued demand for tools and services that support faster treatment and more outpatient care. - Chronic disease management is a major growth engine, with long-term conditions creating steady demand for lower-burden treatment options.

What happened: - The Business Research Company projected the global minimally invasive and non-invasive products and services market will rise from $148.77 billion in 2025 to $160.81 billion in 2026. - The report forecasts the market will reach $216.48 billion by 2030. - The company said the market is being shaped by rising preference for less invasive procedures and wider use of advanced imaging and robotic systems. - North America held the largest market share in 2025.

The details: - The 2025 to 2026 increase implies 8.1% CAGR. - The 2026 to 2030 forecast implies 7.7% CAGR. - Growth drivers cited in the report include better surgical outcomes with fewer complications, improved hospital surgical facilities, and greater acceptance of non-invasive treatment options. - Future growth is expected to come from outpatient and day-care surgeries, broader precision medicine use, cost-efficient surgical solutions and better integration of advanced imaging into surgical workflows. - Anticipated trends include image-guided surgical technologies, more robotic-assisted minimally invasive procedures, wider adoption of non-invasive diagnostics, precision-controlled surgical instruments and a stronger focus on patient safety and faster recovery. - The report defines minimally invasive and non-invasive products and services as medical devices and treatments that avoid entering or breaching the body’s interior. - The report says these approaches exclude instruments that penetrate the skin or body directly. - The report said the technologies can make many procedures safer and more tolerable for patients. - The regional outlook covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - North America’s lead is tied to advanced healthcare infrastructure, high adoption of cutting-edge medical technologies and strong research and development investment. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The release offered a free sample report and the full report through links on The Business Research Company’s website: Free sample report and Full market report.

Between the lines: - The forecast points to a market that is still expanding, but at a slightly slower pace after 2026. - The emphasis on robotics, imaging and precision medicine suggests the market is shifting toward technology-heavy procedures rather than simple device replacement. - Rising pre-diabetes cases in the UK, cited in the release, illustrate how chronic disease prevalence is expanding the need for less invasive treatment paths. - The release said 3,615,330 people registered with general practitioners in the UK were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 cases in 2022.

What's next: - The report expects outpatient surgery, robotic-assisted procedures and image-guided technologies to remain central to market growth through 2030. - Continued chronic disease growth is likely to keep pressure on healthcare systems to adopt faster-recovery treatment options. - Regional competition will likely center on technology adoption, infrastructure and R&D investment, especially in North America and fast-growing global markets.

The bottom line: - Minimally invasive and non-invasive care is moving from a clinical preference to a major commercial market, with technology adoption and chronic disease demand driving the next phase of growth.